ABION Inc. (KOSDAQ:203400)

Market Cap	182.13B
Revenue (ttm)	829.22M
Net Income (ttm)	-45.27B
Shares Out	28.64M
EPS (ttm)	-2,014.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,263
Average Volume	43,379
Open	6,470.00
Previous Close	6,540.00
Day's Range	6,330.00 - 6,530.00
52-Week Range	5,580.00 - 13,000.00
Beta	1.25
RSI	25.18
Earnings Date	Mar 21, 2025

About ABION

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various re...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 203400

Financial Performance

In 2023, ABION's revenue was 1.27 billion, a decrease of -49.16% compared to the previous year's 2.51 billion. Losses were -29.21 billion, 46.6% more than in 2022.